INTRODUCTION
Stem cells have recently received a great deal of attention because of their therapeutic potential for treating human diseases including cancer. 1--3 Stem cells are capable of self-renewal and can generate differentiated progenies for organ development. The differentiation potential is specified as cell potency and stem cells have various degrees of potency such as totipotency, pluripotency and multipotency. 4 According to the origin of stem cells, they are broadly classified into two types: embryonic stem cells (ESCs) isolated from the inner cell mass of blastocysts, and adult stem cells found in various tissues.
Human ESCs (hESCs) are derived from the epiblast tissue of the inner cell mass of a blastocyst or earlier morula stage of embryo. 5 They can quickly proliferate, unlimitedly expand in culture and differentiate into diverse cell types of all adult tissues because of their unique pluripotency. 6 Therefore, hESCs have been considered as a theoretically potential source for regenerative medicine and tissue replacement after injury or disease. However, they are currently facing major limitations for use. Some investigations have described the tumorigenicity of undifferentiated hESCs 7 and the possibility of teratoma formation when injected directly into other bodies. 8 Moreover, the procedures used to collect hESCs from human embryos are associated with substantial moral and ethical issues. 9 Therefore, the treatments using ESCs are not approved at present. Adult stem cells are also known as somatic or germline stem cells and are found in children as well as adults. 10 Most adult stem cells are multipotent, lineage-restricted and are generally referred to by their tissue origins: mesenchymal stem cell (MSC), adipose-derived stem cell, endothelial stem cell and neural stem cell, and so on. 11 Unlike hESCs, the use of adult stem cells in research or therapy is not controversial. Additionally, as adult stem cells can be obtained from the intended recipient for therapeutic purpose, they are immunologically compatible in this case. Adult stem cells have been widely used for research on various cell-based therapies. For instance, previous study reported that bone marrow-derived human multipotent MSCs transplanted resulted in antitumor activity against non-Hodgkin's lymphoma. 12 However, some MSCs have been also shown to increase the in vivo growth of colon cancer, lymphoma and melanoma cells. 13, 14 Therefore, it is unclear whether MSCs promote or suppress tumor growth so far. The difficulties of isolating adult stem cells from diverse tissues such as bone marrow, blood, adipose tissue and brain and expanding them in vitro are another limiting points in their applications because harvesting procedures involve the risks and usually a small number of stem cells can be obtained in a single procedure. 15 Therefore, many studies have been focusing on searching for novel stem cells that can be effectively used for therapeutic purposes without any restrictions.
Recently, amniotic-derived stem cells isolated from human amnion and amniotic fluid have been considered as another potential candidate for stem cell-based therapies and they include human amniotic membrane-derived stem (hAMS) cells and amniotic fluid-derived stem (hAFS) cells. 16--18 They are known for having unique characteristics such as the low expression level of major histocompatibility complex antigens, which may contribute to causing low immunogenicity and anti-inflammation when introduced to other bodies, and a less restricted differentiation potential. In terms of the differentiation potential, they are in an intermediate stage between pluripotent ESCs and lineagerestricted adult stem cells, expressing the transcription factor Oct4 that has a critical role in maintaining pluripotency, but not accomplishing whole differentiation into the three embryonic germ layers (ectoderm, mesoderm and endoderm) and teratoma formation in vivo. 8, 16, 19 Hence, they are often referred to multipotent stem cells and can differentiate into diverse cell types such as adipogenic, osteogenic, myogenic, endothelial, hepatic and also neuronal lines. 17 These stem cells are able to actively self-renew, expand extensively and are not tumorigenic. 8 Additionally, as the applications of amniotic-derived stem cells do not have any ethical objection and their original sources including amniotic membrane and fluid are easily available, they have earned much attention. In this review, we will discuss the possible role of amniotic-derived stem cells for various antitumor modalities as new candidates of human stem cells.
CLASSIFICATION OF AMNIOTIC MEMBRANE/FLUID-DERIVED STEM CELLS
The amnion is a membranous sac that contains the fetus and amniotic fluid, and functions in protecting the developing embryo against various stimuli from the surroundings. 17 It also has an important role during parturition by enhancing the biosynthesis of prostaglandins, which are necessary for the initiation and maintenance of uterine contraction. 15 The amniotic membrane is composed of three major layers of a single epithelial layer, a basement membrane and an avascular mesenchyme ( Figure 1 ). Although none of the three layers contain any nerves, muscles, blood vessels or lymphatic structures, the required nutrients are directly supplied to fetus by diffusion from the amniotic fluid and underlining deciduas. 8 The amniotic epithelium is a monolayer composed of cells uniformly arranged on a basement membrane and in direct contact with the amniotic fluid. The cells of amniotic epithelium secrete glycoproteins, collagens and laminins that comprise the basement membrane, which is supporting the fetus. 8, 20 The amniotic epithelial stem cells are derived from this layer. Under the basement membrane, there is an acelluar compact layer that is the main fibrous skeleton of the amniotic membrane and composed of collagen bundles secreted by mesenchymal cells present in the fibroblast layer. The stromal fibroblast layer is the thickest amniotic cell layer and contains fibroblast-like mesenchymal cells, from which amniotic membrane MSCs are derived. 21 Amniotic fluid filling the inner space of amnion is also an important source of the diverse cell types derived from the developing embryo as well as the amniotic membrane. 8, 16, 17 Therefore, various types of stem cells such as amniotic membranederived epithelial, amniotic membrane-derived mesenchymal and amniotic fluid stem cells can be obtained from the amniotic fluid.
STEM CELL CHARACTERISTICS OF AMNIOTIC MEMBRANE/ FLUID-DERIVED STEM CELLS
Human amniotic membrane-derived epithelial stem cells (hAECs) hAECs are originated from the epithelial layer of amniotic membrane and easily isolated from amnion or amniotic fluid that is readily available during gestation and at the time of birth. These cells have been shown to express the stem cell surface marker proteins such as SSEA-3, SSEA-4, TRA 1-60, TRA 1-81, Thy-1 and ckit. Besides these stem cell markers, hAECs express other molecular markers including OCT4, SOX2 and NANOG, which are required for self-renewal and/or pluripotency. 8,19,22--27 Therefore, hAECs are shown to be able to trilineage differentiation in vitro Figure 1 . The amniotic membrane and amniotic fluid composition. The amniotic membrane is composed of three major layers: a single epithelial layer, a thick basement membrane and an avascular mesenchyme. Amniotic fluid contains diverse types of cells from all three germ layer derived from the skin and digestive tract of the developing embryo, and from the amniotic membrane.
such as differentiations into cells of the pancreatic and hepatic endoderm, neuro-ectoderm and cardiac mesoderm lineages. 28 This differentiation ability of hAECs toward diverse cell types has been actually studied to apply for the therapeutic purposes. For example, Marongiu et al. 29 reported that hAECs may serve as a source of stem cell-derived hepatocytes in transplantation procedures for treating liver disease. After transplantation into the livers of retrorsine-treated SCID/beige mice, naive hAECs differentiated into hepatocyte-like cells. Thus, hAECs possess the ability to differentiate into cells with characteristics of functional hepatocytes both in vitro and in vivo. Furthermore, more extensive studies documented the various differentiations of hAECs into neuron, astrocytes, pancreatic cells, cardiomyocytes, myocytes, osteocytes and adipocytes. 30 Human amniotic membrane-derived MSCs (AM-hMSCs) Amniotic membrane-human MSCs are isolated from amniotic membrane 8, 16, 24, 26 and named AM-hMSCs. AM-hMSCs can be obtained after in vitro culture of term amnion. As the same sort of mesenchymal cells, they have a lot in common in immunophenotypical profile with human bone marrow-derived mesenchymal stromal cells. 31 However, AM-hMSCs express higher levels of OCT4 compared with bone marrow-derived mesenchymal stromal cells, thereby being superior to adult MSCs in their proliferation and differentiation potential. 31 In addition, they are positive for SOX2, REX1, NESTIN (neural stem cell marker), NANOG and CF (stem cell factor, ligand of c-kit). 21, 32 In terms of differentiation potential, AMhMSCs were shown to differentiate in culture toward different cell types such as adipogenic, chondrogenic, osteogenic, skeletal-and cardio-myogenic, endothelial cells, hepatocyte-like cells and neuroglial cells. 33 Zhang et al. 26 have reported that the transplantation of AM-hMSCs significantly decreased hepatic fibrosis and progression of CCl 4 -induced cirrhosis, thereby providing a new approach for the treatment of fibrotic liver disease. In addition, when transplanted in rat heart, they were also shown to survive and to achieve cardiac differentiation without immunological rejection. 34 Human amniotic fluid-derived stem cells (hAFCs) As human amniotic fluid contains the developing embryo and directly contacts with the amniotic membrane during the gestation period, it has diverse cell types derived from an embryo and the amniotic membrane. 17, 35 The presence of hAFCs population in amniotic fluid was firstly identified in 2002 by Prusa et al. 36 and since then, their stem cell characteristics have been extensively studied. hAFCs was shown to express OCT4 mRNA 37 and was scored positive for mesenchymal markers such as CD90, CD105 (SH2), CD73 (SH3/4) and CD166, but negative for hematopoietic markers. 33 Therefore, hAFCs have similar characteristics to human bone marrow MSCs, but are less differentiated. 15, 38 Being OCT4 positive, hAFCs are capable of extensive self-renewal and can differentiate into cells types of the three germ layers such as adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic cells. 8, 16, 32 NON-TUMORIGENICITY OF AMNIOTIC MEMBRANE/FLUID-DERIVED STEM CELLS Tumorigenicity can be a main concern in using stem cells as therapeutic purposes for they have namely the ability to selfrenew and proliferate. Among various types of stem cells, the tumorigenicity is closely linked with the pluripotent stem cells like ESCs. Pre-clinical studies in animal models have reported teratoma formation occurring on injection of mouse ESCs, hESCs or ESCderived cells. 1--4 Therefore, hESCs have a major hurdle to overcome before clinical translation despite their great potential for regenerative medicine along with the ethical concerns. On the other hand, in vivo teratoma formation and tumorigenicity of human amniotic-derived stem cells have not been reported. 15 Actually, when they were transplanted into human volunteers, the non-tumorigenicity has been observed. 15 De Coppi et al. 17 also reported that hAFS cells, unlike ES cells, do not form tumors in vivo and their low risk of tumorigenicity would be advantageous for eventual therapeutic applications. For the details, Sessarego et al. isolated hAM-MSCs and demonstrated their non-tumorigenicity by karyotype analysis. The karyotype of hAM-MSCs was analyzed at different culture passages (fourth and sixth) to monitor the occurrence of spontaneous chromosomal alterations during expansion. The results of this study indicated that hAM-MSCs do not have tumorigenic potential. 12 Phermthai et al. 35 also demonstrated their chromosomal stability by karyotype analysis. When a clonal hAFS cell line was examined after prolonged in vitro culture, hAFS cells appeared to lack chromosomal mutations associated with tumorigenicity because of their chromosomal stability. Luo et al. 25 did not detect any tumor formation when hAECs expressing AAV-GFP (a green fluorescent protein gene) were transplanted into the spleens of SCID nude mice as a partial hepatectomy model. Therefore, it has been concluded that hAMS and hAFS cells may be potentially useful cell source given their non-tumorigenicity, and may be used for various stem cell-based therapeutic procedures.
ANTITUMOR THERAPEUTIC STRATEGIES WITH AMNIOTIC MEMBRANE/FLUID-DERIVED STEM CELLS
Cancer therapeutic strategies include surgery, radiotherapy and chemotherapy. Despite the developments in therapy, cancer mortality rates are high worldwide. Although useful, these modalities do not offer a permanent cure and rather cause various side effects. 39--44 For example, conventional chemotherapeutic drugs, including 5-fluorouracil, are widely used but are associated with various side effects including myelo-suppression, nausea, vomiting, diarrhea and stomatitis. Consequently, there are substantial needs for novel, low toxicity and effective anticancer therapies. 45, 46 Current potential anticancer strategies using stem cells have been regarded as a novel candidate in medical fields and they involve the protocols conducted by either nonengineered or engineered stem cells.
Non-engineered stem cells transplantation strategies
Recently, human stem cell transplantation therapy has drawn attention as an upcoming alternative therapeutic tool in regenerative medicine as well as for the treatment of various diseases including cancer. Several studies have suggested that various human stem cells display antitumor effects. 9,12,23,35,47--51 For example, a study by Ayuzawa et al. 9 demonstrated the significant antitumor effect of transplanted human stem cells. Naive human umbilical cord matrix-derived stem cells were found to significantly attenuate the growth of human breast cancer cells in vitro and in vivo. When co-cultured with MDA 231 human breast carcinoma cells, human umbilical cord matrix-derived stem cell significantly inhibited DNA synthesis in the MDA 231 cells in a dose-dependent manner, thereby leading to tumor growth suppression. Ayuzawa et al. 9 also claimed that human umbilical cord matrix-derived stem cell produced factors such as nitric oxide and various cytokines that attenuate cancer cell growth, perhaps by altering the cell cycle. Furthermore, human fetal skin-derived MSCs inhibited the growth of MCF-7 breast cancer cells in vitro. 52 Cho et al. 53 reported that hyperthermia-treated MSCs (heattreated MSCs) exerted antitumor effects on human carcinoma cells by producing various cytokines such as interleukin (IL) ( Table 1) .
Human amniotic membrane/fluid-derived stem cells may have therapeutic potential in vitro and in vivo and derived promising results as mentioned above. hAMS or hAFS are presumed to express various cytokine factors. When hAMS or hAFS cells are cocultured with human carcinoma cells, the cancer cell viability can be decreased by the presence of hAMS or hAFS expressing cytotoxic factors, that is, tumor necrosis factor-a, transforming growth factor-b, ILs or interferons. In the previous study, we also detected the expressions of tumorcidal factors or cytokines in amniotic-derived stem cells. In a cytokine array analysis and reverse transcription-PCR, hAECs were demonstrated to secrete the various cytokines such as tumor necrosis factor-a, tumor necrosis factor-b, transforming growth factor-b, interferon-g, IL-2, IL-3, IL-4, macrophage colony-stimulating factor and IL-8. When co-cultured with MDA-MB-231 breast cancer cells in vitro, hAECs decreased the viability of cancer cells. In the mouse models xenografted with MDA-MB-231 cells, hAECs effectively targeted the breast tumor and suppressed the tumor volume. 54 Therefore, hAECs appear to serve as mediators that inhibit tumor growth by expressing various cytokines that facilitate tumor cell death. Recently, many other reports also support the relationship between the expression of cytokines in hAMS or hAFS and antitumor effect. It is said that the tumor suppression effect was due to various cytokines produced by AM-hMSCs such as granulocyte macrophage colony-stimulating factor, IL-6, neurotrophin 3, CCL18 (a chemokine), macrophage colony-stimulating factor, brain-derived neutrophic factor, granulocyte chemotactic protein (GCP-2) and conserved dopomine neutrophic factors. 53 In detail, AM-hMSCs may mediate the tumortargeting effects of immunocytes by regulating the expressions of various cytokines such as tumor necrosis factor-a and ILs. 55 For instance, ILs may help immune systems by activating natural killer cells that can directly target human cancers. The results from these studies demonstrated that hAMS and hAFS have potential antitumor effects.
Engineered stem cells strategies Gene therapies using stem cells are widely applied for treating diseases including cancer. 39,44,56--60 Suicide genes can be effectively used for these procedures. 43, 61, 62 As suicide gene can cause a cell to kill itself and surrounding cells via bystander effects, 63--66 it can selectively lead to the cancer cell death if delivered to the tumor formation site. At this point, stem cells are used as vehicles for suicide gene transfer to tumors for the process called genedirected enzyme/prodrug combination (GEPC) therapy. Stem cells are transduced with suicide genes such as cytosine deaminase (CD), carboxylesterase and/or herpes simplex virus thymidinekinase by adenovirus, retrovirus or lentivirus. 41, 42, 57, 67, 68 These suicide genes effectively converts non-toxic prodrugs into their highly cytotoxic forms: 65, 69, 70 CD converts 5-fluorocytosine into 5-fluorouracil, carboxylesterase, CPT-11, SN-38 and herpes simplex virus thymidine-kinase, ganciclovir (GCV), active form of GCV. 62, 64, 67, 69, 71, 72 For example, Gu et al. 73 evaluated the efficacy of the herpes simplex virus thymidine-kinase/GCV system using MSCs (MSCtk cells) in leptomeningeal glioma dissemination models. The results from this study showed that MSCtk cells exerted a strong 'bystander effect' both in vitro and in vivo conditions in the presence of GCV. Joo et al. 74 described the tumor-tropic properties of neural stem cells expressing CD suicide genes (HB1.F3.CD cells) and their ability to target brain tumors. Tumor burdens were significantly reduced in animal models with glioblastoma, medulloblastoma and metastatic neuroblastoma, demonstrating the tumor-targeting properties of the HB1.F3.CD cells in presence of the prodrug 5-fluorocytosine. HB1.F3.CD cells have been used for the development of a novel strategies for delivering therapeutic genes to tumors in the brain. The advantages in using stem cells as delivery vehicles for therapeutic gene transfer may be attributed to their specific tumor tropism. In the previous studies, stem cells were shown to effectively migrate to the cancer cells by reacting to the chemoattractant factors such as stem cell factor, vescular endothelial growth factor-2, C-X-C chemokine receptor type 4 and c-KIT expressed in cancer cells. 1, 3, 60 Meanwhile, the therapeutic potentials of amnionderived stem cells in cancer gene therapy have been recently identified. According to our previous study, hAFCs engineered to express multiple suicide genes, CD and herpes simplex virus thymidine-kinase genes, were shown to significantly inhibit the growth of MDA-MB-231 human breast cancer cells in vitro and reduced the tumor volume of breast cancer xenografted mice in vivo in the presence of the prodrugs, 5-fluorocytosine and GCV. 75 Another recent study also reports that AF-MSCs engineered to express interferon-b can be adopted as therapeutic vehicles for the treatment of bladder cancer by the targeting of the tumor site and further by their high proliferation rate and expansion efficiency in culture. 76 Consequentially, these results indicate that amniotic-derived stem cells can serve as a vehicle in cell-based gene-directed enzyme prodrug system to selectively target malignant cancers. As the studies of engineered stem cells strategies using amnion-derived stem cells are in an early stage, more extensive trials are need to intensify their anticancer potential as therapeutic gene delivery vehicles.
CONCLUSIONS
Human amniotic membrane/fluid-derived stem cells possess a high proliferative potential, express the markers, that is, OCT4 specific to pluripotent stem cells, and have the potential to differentiate into cells of all three germ layers in vitro. Human amniotic-derived stem cells can be divided into three types: hAECs, AM-hMSCs and hAFCs. They are easily obtained from discarded amnions after parturition and their acquisition process is not affiliated with ethical issues. Furthermore, they have advantages when introduced to other bodies because they are non-tumorigenic and cause low immunogenicity and antiinflammation. Anticancer potential of amniotic-derived stem cells suggests a new tool in the stem cell therapy. Novel therapies using hAECs and hAFCs include human stem cell transplantation with non-engineered stem cells and gene-directed enzyme/ prodrug combination therapy with genetically engineered stem cells. In these strategies, amniotic-derived stem cells effectively target the tumor and suppressed the tumor growth by expressing various cytotoxic cytokines. Additionally, they also have a potential as novel delivery vehicles transferring therapeutic genes to the cancer formation sites in GEPC therapy. Taken together, the results of all studies mentioned above indicate that human amniotic membrane/fluid-derived stem cells may exert potent antitumor effects via their tumor-tropic and tumorcidal activities and can be a novel strategy to selectively target human cancers.
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